You are here: Home » News-CM » Companies » News
Business Standard

Invagen Pharmaceutical receives USFDA approval for Pregabalin Capsules

Capital Market 

InvaGen Pharmaceuticals, Inc. (InvaGen), a wholly-owned subsidiary of Cipla announced the receipt of final approval for its Abbreviated New Drug Application (ANDA) for Pregabalin Capsules, 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg and 300mg from the United States Food and Drug Administration (US FDA).

InvaGen's Pregabalin Capsules, 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg and 300mg is AB-rated generic therapeutic equivalent version of Pfizer's Lyrica.

Pregabalin capsules are indicated for:

Management of neuropathic pain associated with diabetic peripheral neuropathy Management of postherpetic neuralgia Adjunctive therapy for the treatment of partial onset seizures in patients 17 years of age and older Management of fibromyalgia Management of neuropathic pain associated with spinal cord injury

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Mon, July 22 2019. 09:06 IST
RECOMMENDED FOR YOU
RECOMMENDED FOR YOU